Transcatheter aortic valve replacement (TAVR) has emerged as a viable treatment option for high-risk patients with severe aortic stenosis (AS) who are not suitable candidates for surgical aortic valve replacement (SAVR). A new study published in JACC: Cardiovascular Interventions shows that the rate of patients with chronic kidney disease (CKD) undergoing TAVR who need to start on dialysis due to kidney related issues post operation is relatively low.
Scientists from the Wellcome Trust Sanger Institute, University College London Cancer Institute and the Royal National Orthopedic Hospital NHS Trust suggest that patients with a rare bone cancer of the skull and spine called chordoma could be helped by existing drugs. This suggestion was made based on the discovery made by scientists that a group of chordoma patients have been found to have mutations in genes that are the target of existing drugs, known as PI3K inhibitors.
Papillary thyroid carcinoma (PTC) is the most common form of thyroid cancer. It is mostly treated with the drug vemurafenib. But most PTC patients develop resistance and progress. However, a research by a Harvard Medical School team found that papillary thyroid carcinoma can be treated effectively with a combination of drugs.